R. LaDuane Clifton compensation by year
ZEVRA THERAPEUTICS Summary Compensation Table · all 8 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $337,500 | $348,500 | $350,200 | $370,993 | $410,975 | $446,480 | $460,867 | $477,307 |
| Bonus | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | — | $0 | $0 | $746,200 | $1,260,373 |
| Option awards | $302,948 | $311,906 | $51,193 | $589,929 | $474,792 | $1,604,822 | $0 | $1,117,274 |
| Non-equity incentive | $0 | $0 | $134,827 | $92,234 | $138,417 | $197,132 | $201,307 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 |
| All other | $6,876 | $4,520 | $4,894 | $13,056 | $13,823 | $14,823 | $41,899 | $966,970 |
| Total | $647,324 | $664,926 | $541,114 | $1,056,212 | $1,038,007 | $2,263,257 | $1,450,273 | $3,821,924 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ZEVRA THERAPEUTICS, INC. DEF 14A filed April 20, 2026, accession 0001434647-26-000025, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ZEVRA THERAPEUTICS, INC. filed document, accession 0001434647-26-000025. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 10,000 | — | $5.98 |
| Option | 4,687 | — | $56.80 |
| Option | 82,423 | — | $9.06 |
| Option | 459,726 | — | $4.54 |
| Option | 2,250 | — | $8.26 |
| Option | 3,125 | — | $201.92 |
| Option | 4,687 | — | $88.00 |
| Option | 10,000 | — | $42.56 |
| Option | 83,486 | — | $7.17 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ZEVRA THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
ZEVRA THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| R. LaDuane Clifton · this page | Former Chief Financial Officer and Treasurer | $3,821,924 |
| Neil McFarlane | President, Chief Executive Officer and Director | $3,782,042 |
| Rahsaan Thompson | Chief Legal Officer, Secretary and Compliance Officer | $1,571,374 |
R. LaDuane Clifton's compensation dossier, ZEVRA THERAPEUTICS
You have read R. LaDuane Clifton's totals and holdings. The dossier adds each equity grant ZEVRA THERAPEUTICS disclosed for R. LaDuane Clifton and ZEVRA THERAPEUTICS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ZEVRA THERAPEUTICS compensation record
free company briefThis page is one person within ZEVRA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ZEVRA THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ZEVRA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ZVRA
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.